RXi Pharmaceuticals said this week that it has formed a collaboration with the University of Massachusetts Medical School's Shalesh Kaushal to develop the company's self-delivering RNAi molecules as therapeutics for ocular diseases.
Conditions that will be a focus of the deal include age-related macular degeneration, RXi said.
Specific terms of the arrangement were not disclosed.